The Chemours Company (NYSE:CC) Receives $17.63 Consensus Price Target from Analysts

The Chemours Company (NYSE:CC) has been assigned a consensus rating of “Hold” from the ten research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $18.1250.

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Chemours in a research note on Saturday, September 27th. Truist Financial raised their price objective on shares of Chemours from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 16th. Zacks Research upgraded shares of Chemours from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 27th. UBS Group raised their price objective on shares of Chemours from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Monday. Finally, Royal Bank Of Canada raised their price objective on shares of Chemours from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, July 3rd.

Insider Buying and Selling

In other news, CEO Denise Dignam acquired 4,068 shares of Chemours stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the transaction, the chief executive officer directly owned 191,546 shares in the company, valued at approximately $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CC. FNY Investment Advisers LLC purchased a new position in Chemours in the first quarter valued at about $27,000. MTM Investment Management LLC purchased a new position in Chemours in the second quarter valued at about $27,000. Farther Finance Advisors LLC increased its holdings in Chemours by 170.7% in the first quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock valued at $30,000 after buying an additional 1,444 shares in the last quarter. UMB Bank n.a. increased its holdings in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock valued at $30,000 after buying an additional 948 shares in the last quarter. Finally, SouthState Corp purchased a new position in Chemours in the first quarter valued at about $34,000. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Price Performance

Shares of CC opened at $15.82 on Tuesday. Chemours has a fifty-two week low of $9.13 and a fifty-two week high of $22.38. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -5.65 and a beta of 1.65. The firm has a 50-day simple moving average of $15.02 and a 200-day simple moving average of $12.99. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The business had revenue of $1.62 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the firm earned $0.38 earnings per share. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts anticipate that Chemours will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were given a $0.0875 dividend. The ex-dividend date was Friday, August 15th. This represents a $0.35 dividend on an annualized basis and a yield of 2.2%. Chemours’s dividend payout ratio (DPR) is presently -12.50%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.